Application Of Adoptive Immunotherapy In Ovarian Cancer

Siyu Yang1
Xiaojiao Yin1
Ying Yue1
Siqing Wang2

1Department of Gynecological Oncology, The First Hospital of Jilin University, Changchun 130061, China; 2Department of Cancer Immunology, The First Hospital of Jilin University, Changchun 130061, China

Abstract: Ovarian cancer (OC) has been the most fatal gynecological disease that threatens women’s health. Surgery and platinum-based chemotherapy are the basic ovarian cancer treatments that can improve survival, but five-year survival rate has not improved because of delayed diagnosis, drug resistance, and recurrence. Novel treatments are needed to improve the prognosis and survival rate of ovarian cancer patients. In recent years, adoptive cell therapy (ACT) has gained increasing attention as an emerging therapeutic strategy in the treatment of solid tumors including OC. ACT has shown promising results in many preclinical and clinical trials of OC. The application of ACT depends on different effector cells, such as lymphokine-activated killer (LAK) cells, tumor-infiltrating lymphocytes (TILs), and genetically modified T cells. In this review, we focus on adoptive immunotherapies in ovarian cancer and summarize completed and ongoing preclinical/trial trials. The future development directions and obstacles for ACT in OC treatment are discussed.

Keywords: ovarian cancer, adoptive cell therapy, cancer immunotherapy, immune cells

Introduction

Ovarian cancer (OC) is the primary gynecological causes of death in women. Worldwide, there are about 230,000 cases of OC each year, with more than 150,000 deaths.1 Surgery and chemotherapy are currently the main treatments for OC. Cytoreductive surgery is used to remove all visible tumor masses. However, most patients are diagnosed in the advanced stage of the tumor and need to receive postoperative adjuvant chemotherapy. In addition, patients with extensive tumor metastasis will receive neoadjuvant chemotherapy to shrink the tumor and destroy metastatic cells, so as to facilitate subsequent surgery and other treatments.2–4 Although radical surgery and adjuvant chemotherapy are performed to remove macroscopic tumors and improve outcomes, most patients with ovarian cancer will have recurrence and tumor resistance, which is usually fatal5 and widely studied anti-vascular endothelial growth factor (VEGF) therapy is also difficult to reverse this situation6 [Table 1]. Thus, there is a great need for more effective OC therapies to improve the long-term clinical prognosis.

With the improved understanding of the relationship between the immune system and tumor development, immunotherapy is becoming a promising treatment for lung cancer,15 melanoma,16 liver cancer,17 and breast cancer.18 In recent years, increasing evidence has shown that immunotherapy is also a promising treatment in ovarian cancer since ovarian cancer is an immunogenic tumor that can be recognized and attacked by immune system.19–21 Recent immune therapies mainly include immune checkpoint inhibitors, cancer vaccine, and adoptive cell therapy...
Immunotherapy

Tumor immunotherapy, such as anti-PD-L1/PD-1 therapies and adoptive therapy, have subsequently demonstrated significant anti-tumor effects. Although immunotherapy is still in its infancy in the clinical treatment of ovarian cancer, many promising preclinical experiments indicate its potential.

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Clinical Efficacy Comparison</th>
<th>Reference</th>
</tr>
</thead>
</table>
| Surgery           | 1. Surgical treatment and chemotherapy are usually used in combination in clinical practice, not alone.  
2. Primary surgery combined with postoperative platinum-taxane chemotherapy has been the standard therapy for advanced ovarian cancer.  
The progression-free and overall survival of complete resection (ideally with no macroscopic residual disease) are improved compared with so-called optimal and suboptimal debulking resection. | 7         |
| Chemotherapy      | 1. Chemotherapy is a milestone in the treatment of ovarian cancer because it improves the outcome in women with ovarian cancer. It can help to achieve no residual tumor (R0) after primary debulking surgery (PDS), or to treat patients by neoadjuvant chemotherapy (NACT).  
2. The clinical efficacy of chemotherapy depends on various factors such as dose, choice of platinum and/or taxane, schedule, mode of administration (intravenous [IV], intraperitoneal [IP]) and so on.  
3. However, some patients will have chemotherapy resistance, and many patients who are cured by chemotherapy will relapse. | 8         |
| Anti-VEGF treatment | 1. Bevacizumab is the most widely studied anti-angiogenesis agent in ovarian cancer.  
2. Two large phase III trials shown that chemotherapy with the addition of bevacizumab significantly improved the progression free survival (PFS) of patients.  
3. However, there is also evidence that bevacizumab has toxicity and side effects such as gastrointestinal (GI) perforation, surgery and wound-healing complications, and hemorrhage.  
4. Only a subset of patients will benefit from anti-angiogenic agents | 9–11      |
| Immunotherapy     | Tumor immunotherapy, such as anti-PD-L1/PD-1 therapies and adoptive therapy, have subsequently demonstrated significant anti-tumor effects. Although immunotherapy is still in its infancy in the clinical treatment of ovarian cancer, many promising preclinical experiments indicate its potential. | 12–14     |

(ACT). Among them, ACT has attracted increasing attention because a large number of specific effector cells against tumor cells results in a quick therapeutic effect and minimizes impact on the internal environment than other therapies.

ACT relies on intravenous infusion of autologous immune cells after stimulation/modification and expansion in vitro to improve autologous antitumor response in tumor patients [Figure 1]. In 1965, Mathé et al confirmed that adoptive immunotherapy had an obvious effect on acute leukemia in a murine experiment and clinical trial. Research on ACT for the treatment of hematological malignancies is constantly evolving and developing.

In 2002, a clinical trial showed that adoptive cell immunotherapy was effective for solid tumors (metastatic melanoma) and ongoing clinical trials have confirmed this. Since OC was not originally considered to be an immunogenic tumor, adoptive immunotherapy for OC did not initially receive much attention. However, in 2003, OC was shown to be an immunogenic tumor that may be treatable by immunotherapy. Adoptive immunotherapy is based on different cell types [Figure 2]: MHC-independent cells (e.g., lymphokine-activated killer (LAK) cells, natural killer (NK) cells, and cytokine-induced killer (CIK) cells) or MHC-dependent cells (tumor-infiltrating lymphocytes (TILs)). There are also two special and rapidly developing cell types: chimeric antigen receptor (CAR) T cells and T cell receptor (TCR) T cells. In this review, we discuss the application of adoptive immunotherapy of LAK cells, NK cells, CIK cells, TILs, CAR-T cells, and TCR-T cells in OC and outline the disadvantages and future development directions of ACT in OC treatment.

**Major Histocompatibility Complex (MHC)-Independent Adoptive Immunotherapy**  
**LAK Cells**

LAK cells are induced by NK cells or T cells through adding high-dose IL-2 and other cytokines when cultured in vitro, rather than an independent lymphoid or subgroup. LAK cells can kill NK-instant tumor cells and have achieved certain therapeutic effects in cancer treatment. In 1985, Rosenberg et al suggested that LAK cells and IL-2 adoptive immunotherapy have therapeutic effects on metastatic tumors for which many traditional treatments are ineffective. Although the number of clinical patients in this study was limited, the same authors had
also shown promising therapeutic effects in their previous in vivo experiments in mice; however, they also mentioned that high-dose IL-2 promotes the secretion of toxic cytokines by helper T cells, which is harmful to patients. Grimm et al also described this problem. Although LAK cell adoptive immunotherapy has a very broad-spectrum anti-tumor effect, the safe application of high-dose IL-2 is still problematic.

NK Cells

NK cells are part of the innate immune response and are key effectors in cancer immunosurveillance. They can defend against cancer development and metastasis without restricting the expression of MHC molecules. NK cells represent about 5–15% of human circulating lymphocytes and comprise CD56\(^+\)CD16\(^-\) NK cells and CD56\(^-\)CD16\(^+\) NK cells. CD56\(^+\)CD16\(^-\) NK cells with high cytotoxic potential can produce plenty of cytokines, while CD56\(^-\)CD16\(^+\) NK cells are highly cytotoxic and mediate antibody-dependent cellular cytotoxicity (ADCC) responses. NK cells can effectively treat tumors such as leukemia, but the therapeutic effect of NK cell adoptive immunotherapy in OC is still being explored. The promise of NK cell adoptive immunotherapy for OC was recognized in 2007, and it was shown that resting NK cells rely on DNAM-1 signaling with complementary contributions of NKG2D and NCR receptors to recognize and kill freshly isolated OC cells in vitro. In 2006, a new mouse model was established that will be helpful for further exploration of NK cell adoptive immunotherapy for OC.

CIK Cells

CIK cells were first discovered in 1991 by Schmidt-Wolf et al. They were heterogeneous CD8\(^+\) T cells produced by human peripheral blood lymphocytes (PBLs) and induced by addition anti-CD3 antibody, interferon-\(\gamma\) (IFN-\(\gamma\)), and interleukin-2 (IL-2) ex vivo. CIK cells can be characterized by the presence of CD3\(^+\) CD56\(^-\) phenotype, which is mainly responsible for the antitumor activity of CIK cells and CD3\(^+\) CD56\(^-\) phenotype, which is more similar to conventional T lymphocytes.

Several studies have confirmed the feasibility, effectiveness, and safety of CIKs for the treatment of malignant tumors. Leemhuis et al confirmed the effectiveness of CIK cells in the treatment of malignant tumors, and then conducted a clinical phase I trial of CIK cell therapy in patients with hematologic malignancies. Clinical phase I trials of patients with hematologic malignancies by Introna et al also demonstrated that it was feasible and well tolerated to produce allogeneic CIK cells under clinical conditions. Another study analyzed the efficacy of CIK cells in the treatment of OC. In a phase II study, Liu et al tested the effectiveness of CIK cell therapy following first-line treatment in advanced OC. Further experiments are required to determine whether CIK cell maintenance immunotherapy can help improve overall survival, but CIK cell therapy does improve progression-free survival in patients with advanced OC after first-line treatment with slight toxicity. A retrospective analysis by Zhou et al further validated the effectiveness of CIK cell therapy as a therapeutic approach to prolonging the survival of OC patients. A clinical phase II trial to determine whether radiofrequency ablation (RFA) and cytokine-induced killer
cell (CIK) infusion can prolong survival in patients with OC and more attention. Genetically modified T cells can express a chimeric antigen receptor (CAR) or a tumor-antigen specific T-cell receptor (TCR).

**CAR-T Cell Therapy**

CAR-T cells are T lymphocytes that have been genetically modified to express an engineered T cell receptor that is able to recognize tumor-specific antigens MHC unrestrictedly and activate the immune response.

The CAR comprises four main parts: the extracellular antigen-binding domain, the spacer domain (hinge domain), the transmembrane domain, and the intracellular T cell activation/signaling domain. The extracellular antigen-binding domain, also known as the ectodomain, is derived from the light and heavy chains of the antibody and is a single-chain variable fragment (scFv) that can recognize tumor-specific antigens on cell surface in an MHC-unrestricted manner.68–61 The CAR-T cell structure design has been constantly updated, through four generations, producing CAR-T cells that survive longer in vivo and have stronger killing ability [Figure 3]. The first generation of CAR-T cells only contained the extracellular scFv antigen recognition region and the intracellular CD3ζ chain signal region. To improve the proliferation and persistence of CAR-T cells, the costimulatory molecules such as CD28 and OX-40/4-1BB (CD134/CD137) were added in the second and third generation. The fourth generation is characterized by releasing cytokines like IL-12 and IL-15, which enhance immune response.61,62

The most exciting results with CAR-T cell therapy have been achieved in hematological tumors. In a phase I clinical trial conducted by Park et al,63 53 patients with relapsed B-cell acute lymphoblastic leukemia (ALL) received an infusion of autologous T cells expressing the 19-28z CAR. Long-term follow-up of outcomes and safety indicated that 19-28z CAR-T cells have potent anti-tumor capability with many patients achieving long-term relief and possibly cure.63 Currently, anti-CD19 CAR-T cells are approved by the FDA for the treatment of diffuse large B-cell lymphoma. Brudno et al’s study of CAR-BCMA (B-cell maturation antigen) T cells in the treatment of multiple myeloma also confirmed the enormous potential of CAR-T cells in hematological tumor treatment.64 Research on CAR-T cell therapy continues to extend to solid tumors including OC.

The main targets for CAR-T cells in OC include MUC16, mesothelin and folate receptor-alpha. Preclinical studies of CAR-T cell therapy targeting MUC16 in murine models have shown...
promising results suggesting that this approach may be effective for the treatment of OC, and a parallel clinical trial is ongoing. MUC16 plays an important role in the progression and metastasis of OC and has become a key target for OC treatment. Mesothelin is an antigen target that is overexpressed in OC. The expression of mesothelin is associated with the prognosis of OC; hence, mesothelin is both a therapeutic target for OC and a prognostic marker. The results of preliminary trials are promising, and more clinical trials on CAR-T cell therapy targeting mesothelin are still ongoing, such as NCT03692637 and NCT03814447. Folate receptor-α (FRα) is a glycosylphosphatidylinositol-anchored protein that expressed on the surface of normal ovarian cells. FRα is also overexpressed on the surface of malignant epithelial cancer cells, making it a potential target for the treatment of OC. The safety and efficacy of CAR-T cell therapy targeting FRα are supported by preclinical studies and phase I clinical trials. Another clinical trial (NCT03585764) is also underway. Other antigens such as HER2 and CD133 have also been tested in preclinical animal models for OC therapy (NCT01935843, NCT02541370).

Although CAR-T cell therapy has shown great potential in the treatment of OC, it still faces many problems that remain to be solved. The CAR target antigen is also expressed in some normal tissue, resulting in immune-mediated rejection that is known as an “on-target, off-tumor” response. This rejection can even cause damage to vital organs such as the liver and lungs. Also, the potentially immunosuppressive environment in OC, including the highly immunosuppressive ascites, will prevent T cells from effectively infiltrating into tumor cells and dysfunctional T cells. CAR-T cell adoptive immunotherapy also has some common problems of ACT treatment, such as cytokine release syndrome and a more effective T cell transport pathway. In conclusion, there are both hopes and challenges in the treatment of OC by CAR. Further research is necessary to improve the safety and efficacy of CAR-T cell therapy in OC.

**TCR-T Cell Therapy**

TCRs are characteristic markers on the surface of T cells that recognize specific antigens. TCR-T cells are T cells that express a genetically engineered TCR alpha and beta chain pair that can recognize tumor-specific antigens. TCR-T cell treatment has been successful in patients with malignant cancer such as colorectal carcinoma, metastatic melanoma, and multiple myeloma. Genetically modified TCR-T cells are also considered as a potentially promising treatment for OC patients. In OC, the TCR target antigens include MAGE-A4, WT1, and NY-ESO-1, with NY-ESO-1 being widely studied.

New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is an 18 kDa protein that can be detected in normal testis, fetal ovary, and placenta. However, NY-ESO-1
antibodies can also be detected in the serum of ovarian cancer, lung cancer, breast cancer, bladder cancer, esophageal cancer, as well as melanoma patients. Odunsi et al detected the expression of NY-ESO-1 by reverse transcription PCR (RT-PCR) and immunohistochemistry (IHC) in OC tissues and cell lines, confirming its expression and persistence in OC. Thus, NY-ESO-1 is an attractive target for antigen-specific adoptive immunotherapy in OC. Several phase I/II clinical trials with TCR-T cells are currently ongoing in OC patients (NCT01567891, NCT03691376, NCT02457650, NCT02869217, NCT03159585). Like other types of ACT, there are barriers to the application of TCR-T cells to ACT. Tumor antigen-specific T cells of autoantigens isolated from cancer patients usually have low affinity due to central tolerance. As observed with CAR-T cells, the “on-target, off-tumor” response occurs when TCR-T cells are infused, due to the expression of the same antigen on normal tissue, and the infused TCR-T cells also induce the occurrence of cytokine release syndrome (CRS).

Although both TCR-T cells and CAR-T cells are genetically modified, they have several differences. Since TCRs can recognize epitopes from both intracellular and cell surface antigens of tumor cells via TAA/MHC complex, tumor-specific TCRs can only be used in patients with the specific MHC or HLA allele. In contrast, CAR recognition does not rely on peptide processing or MHC molecules; hence, CARs can only recognize tumor surface antigens; however, all surface target molecules may become potential CAR trigger epitopes.

**Obstacles For ACT In OC**

**Immunosuppressive Tumor Microenvironment**

Immune suppression in tumor microenvironment (TME) is mediated by three main factors: 1) immunosuppressive cells in the TME; 2) cytokines and enzymes released from the tumor or myeloid cells; and 3) barriers. An immunosuppressive TME seriously affects the therapeutic effect of ACT on tumors, especially in OC, which can build a highly suppressive environment in the peritoneal cavity.

T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) are both important immunosuppressive cells in the OC TME. Tregs can induce immunosuppressive cytokines such as IL-10 and TGF-β to suppress the function of tumor-infiltrating cytotoxic T cells in the OC environment. MDSCs express high levels of substances such as arginase, inducible nitric oxide synthase (iNOS), and reactive oxygen species (ROS) to inhibit T-cell function. In order to reduce immunosuppression in TME, non-myeloablative chemotherapy can be used to decrease the number of Tregs and suppressive cellular cytokines. This can also be achieved by combinations of ACT with immune checkpoint inhibitors and targeted therapies.

Some cytokines and enzymes released from the tumor or myeloid cells also can suppress the immune response. High expression of vascular endothelial growth factor (VEGF), which is expressed in most OC, can recruit MDSCs to the tumor site and inhibited tumor immunity in ovarian carcinoma. In tumor cells, the high expression of TGF-β will inhibit the function of human memory CD8+ T cells and tumor-infiltrating lymphocytes. Indoleamine 2,3-dioxygenase (IDO) is an enzyme that catalyzes the degradation of tryptophan, which in turn inhibits T cell proliferation. In addition, IDO can directly inhibit T cells and enhance local Treg-mediated immunosuppression. To solve the immunosuppression caused by these cytokines and enzymes, we can combine antagonists and blocking antibodies for different targets with ACT treatment.

Tumor vasculature and tumor stroma are both common barriers that prevent homing of effector T cells. Leung et al suggested that cancer-associated fibroblasts (CAFs) can upregulate the lipoma-preferred partner (LPP) and this was correlated with survival and chemoresistance in patients with OC. They demonstrate the importance of CAF–endothelial cell crosstalk signaling in cancer treatment and the strategy of using LPP targeting siRNA in combination with cytotoxic drugs to improve treatment efficacy. Antiangiogenic agents are also being used to normalize the tumor vasculature and reduce the tumor metastasis in OC. A recent study showed that losartan has the effect of reducing collagen content as well as improving perfusion and relieving tumor hypoxia, and this is helpful to enhance chemotherapeutic efficacy in OC models.

**Cytokine Release Syndrome (CRS)**

CRS is a potentially life-threatening acute inflammation that occurs after ACT infusion in hematologic and solid tumor patients. The typical clinical manifestations of CRS include constitutional symptoms like fever, malaise, anorexia, and myalgias, and organic damage like cardiac dysfunction, respiratory distress syndrome, and renal/hepatic/neurologic toxicity. CRS is caused by a massive cytokine release by the infused T
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Status</th>
<th>Conditions</th>
<th>Type of Adoptive Therapy</th>
<th>Primary Outcome</th>
<th>Secondary Outcome</th>
<th>Adverse Events</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03692637</td>
<td>Not yet recruiting</td>
<td>Epithelial Ovarian Cancer</td>
<td>Anti-Mesothelin CAR NK Cells</td>
<td>Occurrence of treatment-related adverse events</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>NCT03539406</td>
<td>Not yet recruiting</td>
<td>Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma</td>
<td>UCB-NK cells</td>
<td>Incidence of treatment emergent adverse events</td>
<td>1. In vivo lifespan and expansion of the infused UCB-NK cells</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2. Measurement of in vitro cytolytic activity of infused NK cells</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3. The effect of NK cell infusion on measurable disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00652899</td>
<td>Terminated</td>
<td>Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer</td>
<td>Allogeneic natural killer cells</td>
<td>Number of patients with in vivo expansion of infused allogeneic natural killer (NK) cell product</td>
<td>1. Number of patients per disease response</td>
<td>Hemolysis, Edema, Death - disease progression, NOS, Fatigue, Fever, Dyspnea and so on</td>
<td>1. None of the patients met the counting criteria in primary outcome. 2. None of the patients had complete response, but most of patients had partial response or stable disease. 3. Median number of days to progression was around 100 days. 4. The median number of days survived after treatment was 291 for patients who did not receive total body irradiation per protocol, whereas it was 171.5 for patients who receive total body irradiation</td>
<td>/</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Status</th>
<th>Conditions</th>
<th>Type of Adoptive Therapy</th>
<th>Primary Outcome</th>
<th>Secondary Outcome</th>
<th>Adverse Events</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02487693</td>
<td>Active, not recruiting</td>
<td>Ovarian Carcinoma</td>
<td>Autologous cytokine-induced killer cells</td>
<td>Recurrence-free survival</td>
<td>Adverse events related to CIK treatments.</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>NCT02482090</td>
<td>Completed</td>
<td>Metastatic Ovarian Cancer</td>
<td>TIL infusion</td>
<td>Number and type of reported adverse events</td>
<td>1. Treatment-related immune responses</td>
<td>/</td>
<td>Young TILs could be expanded to clinical numbers. Autologous tumor cells are found in TILs in more than 50% of patients. Antigen-specific TILs could be isolated and further expanded in vitro. These findings suggested that ACT with TILs could be beneficial to patients with OC.</td>
<td>53</td>
</tr>
<tr>
<td>NCT03287674</td>
<td>Active, not recruiting</td>
<td>Metastatic Ovarian Cancer</td>
<td>TIL infusion</td>
<td>Determine the safety of TIL therapy in combination with checkpoint inhibitors</td>
<td>1. Treatment-related immune responses</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>NCT03412526</td>
<td>Recruiting</td>
<td>Metastatic Ovarian Cancer</td>
<td>TIL infusion</td>
<td>1. Objective tumor responses</td>
<td>1. OS and PFS</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>NCT03610490</td>
<td>Recruiting</td>
<td>Ovarian Carcinosarcoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Ovarian Carcinoma, etc</td>
<td>Autologous Tumor Infiltrating Lymphocytes MDA-TIL</td>
<td>ORR</td>
<td>1. Complete response rate (CRR)</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Status</th>
<th>Conditions</th>
<th>Type of Adoptive Therapy</th>
<th>Primary Outcome</th>
<th>Secondary Outcome</th>
<th>Adverse Events</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
</table>
| NCT01883297 | Recruiting        | Recurrent, Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, etc | Re-stimulated tumor-infiltrating lymphocytes (TILs) | Number occurrences and severity of side effects | 1. Clinical response to treatment  
2. Number of patients with an immunity and no immunity to the study treatment | /              | /              | /         |
| NCT04025216 | Not yet recruiting | Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer, Multiple Myeloma, Pancreatic Ductal Adenocarcinoma | TnMUC1-Targeted Genetically Modified Chimeric Antigen (CAR) | 1. Phase 1: Dose Identification of CART-TnMUC1  
2. Phase 1a Expansion: Objective Response in platinum-resistant ovarian cancer | 1. Safety, tolerability and feasibility of CART-TnMUC1  
2. Preliminary anti-tumor efficacy of CART as assessed by OS, PFS, ORR, Clinical Benefit Rate, DOR and Time to Response  
3. Expression of TnMUC1  
4. Peripheral expansion and persistence of CART-TnMUC1 cells | /              | /              | /         |
| NCT01583686 | Terminated        | Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Lung Cancer | Anti-mesothelin CAR transduced PBL | 1. Frequency and severity of treatment-related adverse events  
2. Percentage of patients who have a clinical response to treatment | In vivo survival of CAR gene-engineered cells | /              | Currently, the study only obtained experimental results related to monoclonal antibodies and published articles. | 113,114 |
| NCT03916679 | Recruiting        | Ovarian Cancer                                                              | Anti-MESO CAR-T cells                  | Safety measured by occurrence of study-related adverse effects | 1. Overall complete remission rate  
2. PFS after administration  
3. Duration of CAR-positive T cells in circulation  
4. Detection of PD-1 antibody in serum | /              | /              | /         |

(Continued)
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Status</th>
<th>Conditions</th>
<th>Type of Adoptive Therapy</th>
<th>Primary Outcome</th>
<th>Secondary Outcome</th>
<th>Adverse Events</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03585764</td>
<td>Recruiting</td>
<td>Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma</td>
<td>MOv19-BBz CAR T cells</td>
<td>Number of study subjects with treatment-related adverse events</td>
<td>1. Tumor response rates 2. OS, PFS and ORR</td>
<td>/</td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>NCT02830724</td>
<td>Recruiting</td>
<td>Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer</td>
<td>Anti-hCD70 CAR transduced PBL</td>
<td>1. Maximum tolerated cell dose (MTD) 2. Percentage of patients who have a clinical response to treatment (objective tumor regression)</td>
<td>1. In vivo survival of anti-hCD70 CAR transduced cells 2. Frequency and severity of treatment-related adverse events</td>
<td>/</td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>NCT03814447</td>
<td>Recruiting</td>
<td>Ovarian Cancer</td>
<td>Anti- MESO CAR-T cells</td>
<td>Adverse events (AEs) and Serious adverse event (SAEs)</td>
<td>1. The highest concentration (Cmax), the time to reach the highest concentration (Tmax) and the area under the curve of 30 days of anti-human MESS T cells in the peripheral blood after administration 2. ORR and PFS after administration</td>
<td>/</td>
<td>/</td>
<td></td>
</tr>
<tr>
<td>NCT02541370</td>
<td>Unknown</td>
<td>Ovarian Tumor, Colorectal Cancer, Acute Myeloid and Lymphoid Leukemias, etc</td>
<td>Anti-CD133 CAR T cells</td>
<td>Occurrence of study-related adverse events</td>
<td>Anti-tumor responses to CART-133 cell infusions</td>
<td>Mild chills, Fever, Fatigue, Vomiting and Muscle soreness, etc</td>
<td>Currently, the study only obtained experimental results related to cholangiocarcinoma with published articles.</td>
<td>115</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Status</th>
<th>Conditions</th>
<th>Type of Adoptive Therapy</th>
<th>Primary Outcome</th>
<th>Secondary Outcome</th>
<th>Adverse Events</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
</table>
| NCT01567891 | Completed    | Ovarian Cancer                    | NY-ESO-1\textsuperscript{c} T cells | Number of participants with adverse events related to study treatment         | 1. Tumor response  
2. Peak persistence of modified T-cells in the peripheral blood  
3. Determine functional properties and phenotype of modified T-cells from peripheral blood  
4. Correlate NY-ESO-1 expression in tumor tissue before treatment with archival tumor tissue to assess impact of therapy on expression of NY-ESO-1 protein | Febrile neutropenia, Cytokine Release Syndrome, Anemia, Sinus Tachycardia, Nausea, White blood cell and neutrophil count decreased, etc | 1. 5 out of 6 patients developed adverse events related to study treatment  
2. No patient has a tumor response within the specified time range  
3. Peak persistence of NY-ESO-1\textsuperscript{c} T cells in the peripheral blood is 85,862.6 copies of WPRE/mcg of genomic PBMC DNA  
4. In the manufactured product and post-treatment blood, the percentage of CD4\textsuperscript{a}pentamer\textsuperscript{a} or CD8\textsuperscript{a}pentamer\textsuperscript{a} cells expressing LAG-3, PD-1, TIM-3 in the functionality of NY-ESO-1\textsuperscript{c} T cells  
5. Data was only collected from 2 subjects. The Archival/ Baseline H scores of 2 subjects were 50/15 and 100/0 respectively. | / |
| NCT03159585 | Recruiting   | Stage IV of Ovarian Cancer, Esophageal Cancer, Bladder Carcinoma, etc | NY-ESO-1-\textsuperscript{specific} TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) | The treatment-related adverse events of the patients received TAEST16001 treatment | Assess ORR, DOR, time to progress, PFS, OS and the expression of tumor markers | / | / | / |

*Table 2 (Continued).*
<table>
<thead>
<tr>
<th>NCT Number</th>
<th>Status</th>
<th>Conditions</th>
<th>Type of Adoptive Therapy</th>
<th>Primary Outcome</th>
<th>Secondary Outcome</th>
<th>Adverse Events</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02457650</td>
<td>Recruiting</td>
<td>Ovarian Cancer, Bladder Carcinoma, Breast Cancer, Esophagus Carcinoma, Lung Cancer, etc</td>
<td>Anti-NY ESO-1 TCR-transduced T cells</td>
<td>Evaluate the safety and feasibility of the administration of anti-NY-ESO-1 TCR transduced T cells in patients with HLA-A2+ NY-ESO-1-expressing malignancies.</td>
<td>Determine if the treatment can result in clinical regression of malignant tumors in the patients.</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>NCT02869217</td>
<td>Recruiting</td>
<td>Ovarian Cancer, Lung Cancer, Bladder Cancer, Liver Cancer</td>
<td>NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes (TBI-1301)</td>
<td>1. Safety profile 2. Recommended phase 2 (RP2D) dose TBI-1301 when administered following cyclophosphamide pre-treatment</td>
<td>Evidence of efficacy (i.e. anti-tumor effect) of TBI-1301</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>
cells or other immune cells that are activated as they recognize tumor antigens. IL-6 is a crucial mediator in CRS and is therefore an important target for the treatment of CRS. An antagonist of IL-6 receptor, tocilizumab, can alleviate the toxicity of CRS without affecting the therapeutic effect of ACT.

On-Target, Off-Tumor Toxicity

“Tumor-specific” antigens are also commonly expressed in normal tissues, which results in an on-target, off-tumor immune response after stimulation of T cells in ACT. If these antigens are expressed in vital organs, such as heart, liver, and kidney, they will cause fatal damage. The fundamental solution to this problem is to select tumor-specific antigens that are not expressed in normal tissues, but this is difficult. To overcome this, Kloss et al proposed a method where T cells are transduced with both a CAR, offering suboptimal activation upon binding of one antigen, and a chimeric costimulatory receptor (CCR) that recognizes a second antigen. This technology has made progress in OC. Lanitis et al generated trans-signaling T cells with two distinct CARs: anti-Meso scFv-CD3ζ and anti-FRα scFv-CD28. Both FRα and mesothelin show high expression in OC tissue, compared to much lower expression in normal tissues. The trans-signaling CAR strategy can more accurately identify tumor cells and diminish damage to normal tissues.

Future Perspective

Many clinical trials of ACT for ovarian cancer are ongoing. However, owing to the complexity of the OC tumor microenvironment and the human immune system, there are still many problems to be solved in the ACT treatment of OC. For example, how to reduce costs while ensuring efficient production of effector cells; and how infused T cells could home in on the tumor site and infiltrate it more accurately. Furthermore, many of the current clinical and preclinical experiments lack randomness, and more randomized trials are needed to confirm that ACT can improve overall survival (OS) or progression-free survival (PFS) in patients with ovarian cancer.

Nonetheless, in preclinical and clinical trials, the efficacy of ACT in OC is promising. Therefore, ACT still shows potential to become the new effective therapy for OC if we can address the abovementioned obstacles to reduce toxicity and improve the efficiency of ACT. The immune response inhibition caused by the tumor microenvironment can be reduced by combining the application of immunological checkpoint inhibitors or anti-angiogenesis agents, enabling improved effector cell function. In addition, new technology is evolving that utilizes two different CARs on T cells, enabling effector cells to more accurately identify tumor cells and improving their antitumor efficacy. Cell metabolism plays an important role in the anti-tumor effect of immune cells. Increasingly, studies have shown that the regulation of immune cell metabolism can affect the immune response; therefore, regulation of the effector cell metabolism process may be another approach to improve the anti-tumor effect and efficacy of ACT. Further refinement of technologies will hopefully generate more successful treatment methods for ovarian cancer.

Disclosure

The authors report no conflicts of interest in this work.

References


77. van der Merwe PA, Davis SJ. Molecular interactions mediating T cell activation. Nat Rev Immunol. 2003;3(11):822–834. doi:10.1038/nri1188


